European real-world use of belumosudil for the treatment of cGvHD

Chronic graft-versus-host disease (cGvHD) affects up to 70% of allogeneic hematopoietic stem cell transplantation recipients.¹ Nearly 50% of patients with cGvHD require third-line treatment, yet therapeutic options available for patients at this late stage of the disease have remained limited.²

Belumosudil, a selective Rho-associated coiled-coil-containing protein kinase 2 (ROCK 2) inhibitor, is approved by the U.S. Food and Drug Administration (FDA) and recently received conditional marketing authorization from the European Commission for the treatment of patients with cGvHD who have received at least two prior lines of therapy.^3,4 While these approvals are supported by safety and efficacy data from clinical trials and real-world evidence, the latter provides additional insights into the effectiveness of belumosudil and enables validation of trial outcomes in routine practice.

This visual abstract summarizes real-world experience of belumosudil in patients with cGvHD across three European analyses.

This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content.